Warning Letter On Adverse Event Reporting May Stem As Much From Jazz Reaction As REMS Problem
This article was originally published in The Pink Sheet Daily
Executive Summary
Jazz Pharmaceuticals initially admitted it had known about 10 deaths and 64 other serious, unexpected adverse drug experiences associated with its cataplexy drug Xyrem, but later changed its story, FDA says.